Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, we report on new data showing Wegovy’s potential to reduce liver injury in patients with MASH, Eli Lilly’s latest strategic collaborations in gene therapy, and Novo Nordisk’s decision not to increase its acquisition offer for Metsera following Pfizer’s entry.
Novo Nordisk announced new data demonstrating that Wegovy (semaglutide) may reduce liver injury markers in patients with metabolic dysfunction–associated steatohepatitis (MASH). The results, presented in a late-breaking clinical session, suggest GLP-1 therapies could play a key role in managing both obesity and liver-related metabolic diseases. Analysts say this finding may strengthen Novo Nordisk’s position as it expands into adjacent therapeutic areas beyond diabetes and weight management.
Meanwhile, Eli Lilly is deepening its footprint in gene therapy through new strategic collaborations with MeiraGTx and SaneGeneBio. The agreements aim to accelerate research in ocular and neurological disorders, leveraging next-generation vector technologies and manufacturing platforms. These moves continue Lilly’s aggressive R&D diversification strategy, complementing its leadership in obesity and diabetes markets.
In other news, Novo Nordisk confirmed it will not increase its acquisition proposal for Metsera, despite Pfizer’s competing bid for the metabolic disease biotech. The decision signals a disciplined approach to deal-making amid heightened competition for metabolic assets. Market watchers note that both offers reflect the growing strategic value of companies advancing GLP-1–adjacent or complementary therapies.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
